DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology

References

Ribas A, Puzanov I, Dummer R. et al.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Lancet Oncol 2015;
16 (08) 908-918

Download Bibliographical Data

Access:
Access: